What the superinvestors bought and sold in 2024 Q4
2024 Q4
136 of 137 filedThe quarter at a glance
82 of 134 managers were net sellers. Setting price aside, they took $52.7B out, led by Information Technology (−$23.2B), while adding to Health Care (+$7.9B). FERG was the most widely bought stock (7 bought, 0 sold); AMZN the most widely sold (23 sold, 11 bought).
Net buyers
47 of 134 managers
82 sold more than they bought · 5 about even
Net bought
−$52.7B
Price moves taken out; prices alone moved the book +$15.8B.
Positions opened
633
593 closed out. IPOs, spin-offs and mergers left out.
Combined book, last quarter
+2.6%
SPY +2.1%,
0.4 pts ahead.
Price only.
Most bought and sold
Ranked by how many managers bought minus how many sold, with price moves taken out. Open a stock to see who.
Most bought
-
1 FERG Ferguson Enterprises Inc. 7 bought · 0 sold +$366M
Bought by
- Seth Klarman - Baupost Group opened 5.7% of book
- Dan Loeb - Third Point added 2.6% → 2.8%
- William Von Mueffling - Cantillon Capital Management added 2.1% → 2.2%
- Gavin Baker - Atreides Management opened 1.1% of book
- Francois Rochon - Giverny Capital opened 0.21% of book
- Thomas Gayner - Markel Group added 0.15% → 0.16%
- Polen Capital Management opened <0.01% of book
Sold by
No manager sold.
-
2 BA Boeing Co. 8 bought · 2 sold +$786M
Bought by
- King Street Capital Management opened 29.2% of book
- Hillman Capital Management added 2.5% → 3.7%
- Nehal Chopra - Ratan Capital Management opened 3.2% of book
- Andreas Halvorsen - Viking Global Investors opened 1.7% of book
- Sarah Ketterer - Causeway Capital Management added 0.14% → 1.2%
- George Soros - Soros Fund Management added 0.06% → 0.14%
- Steven Check - Check Capital Management opened <0.01% of book
- Mairs & Power added <0.01% → <0.01%
Sold by
- Davidson Kempner Capital Management closed was 0.16%
- Murray Stahl - Horizon Kinetics Asset Management cut <0.01% → <0.01%
-
3 GBTC Ishares Bitcoin Trust ETF 6 bought · 0 sold +$429M
Bought by
- Nehal Chopra - Ratan Capital Management opened 5.1% of book
- Farallon Capital Management added 0.25% → 2.0%
- Corvex Management opened 1.7% of book
- Samantha Mclemore - Patient Capital Management added 0.26% → 1.2%
- Senator Investment Group opened 0.13% of book
- Francois Rochon - Giverny Capital opened 0.02% of book
Sold by
No manager sold.
-
4 BLK Blackrock Inc. 6 bought · 0 sold +$282M
Bought by
- William Von Mueffling - Cantillon Capital Management added 2.8% → 3.0%
- Thomas Gayner - Markel Group added 1.9% → 2.0%
- Bill Nygren / Oakmark - Harris Associates L P opened 0.31% of book
- Hillman Capital Management opened 0.13% of book
- Ron Baron - Bamco Inc. (Baron Capital) added <0.01% → <0.01%
- Dodge & Cox added <0.01% → <0.01%
Sold by
No manager sold.
-
5 EOG Eog Res Inc. 6 bought · 0 sold +$215M
Bought by
- Torray Investment Partners added 2.4% → 2.6%
- Don Yacktman - Yacktman Asset Management added 2.1% → 2.6%
- Harry Burn - Sound Shore Management opened 2.1% of book
- Bill Nygren / Oakmark - Harris Associates L P added 1.1% → 1.3%
- Murphy Pohlad - Murphy Pohlad Asset Management opened 0.09% of book
- Bruce Berkowitz - Fairholme Capital Management opened 0.02% of book
Sold by
No manager sold.
-
6 LLY Eli Lilly & Co. 8 bought · 3 sold +$1.7B
Bought by
- Stephen Mandel - Lone Pine Capital opened 4.5% of book
- Chase Coleman - Tiger Global Management added 3.7% → 3.8%
- Polen Capital Management added 1.1% → 2.7%
- John Armitage - Egerton Capital (UK) opened 2.5% of book
- Nehal Chopra - Ratan Capital Management added 2.9% → 1.9%
- Senator Investment Group added 0.93% → 1.9%
- Stanley Druckenmiller - Duquesne Family Office opened 1.3% of book
- George Soros - Soros Fund Management opened 0.39% of book
Sold by
- Philippe Laffont - Coatue Management cut 0.82% → 0.56%
- Andreas Halvorsen - Viking Global Investors closed was 0.49%
- Ron Baron - Bamco Inc. (Baron Capital) cut 0.05% → 0.04%
-
7 ELV Elevance Health Inc. 7 bought · 2 sold +$1.5B
Bought by
- Ruane, Cunniff & Goldfarb added 8.2% → 7.2%
- Dan Sundheim - D1 Capital Partners opened 4.9% of book
- Leon Cooperman - Omega Advisors added 3.8% → 3.9%
- First Eagle Investment Management added 2.3% → 2.7%
- Vulcan Value Partners added 2.4% → 2.4%
- Arnold Van Den Berg - Van Den Berg Management I added 1.7% → 1.8%
- Bill Nygren / Oakmark - Harris Associates L P opened 0.88% of book
Sold by
- Harry Burn - Sound Shore Management closed was 2.0%
- Ron Baron - Bamco Inc. (Baron Capital) closed was 0.02%
-
8 EFX Equifax Inc. 5 bought · 0 sold +$535M
Bought by
- Ako Capital added 2.1% → 2.6%
- Wallace Weitz - Weitz Investment Management added 2.5% → 2.5%
- Bill Nygren / Oakmark - Harris Associates L P added 0.70% → 1.2%
- Dev Kantesaria - Valley Forge Capital Management opened 0.81% of book
- Robert Olstein - Olstein Capital Management added 0.40% → 0.58%
Sold by
No manager sold.
-
9 FLUT Flutter Entmt PLC 7 bought · 2 sold +$531M
Bought by
- Stephen Mandel - Lone Pine Capital opened 3.7% of book
- Dan Loeb - Third Point added 1.6% → 3.0%
- Brad Gerstner - Altimeter Capital Management opened 1.8% of book
- Senator Investment Group added 0.73% → 1.6%
- Lee Ainslie - Maverick Capital added 1.0% → 1.1%
- George Soros - Soros Fund Management added 0.39% → 0.59%
- Farallon Capital Management added 0.06% → 0.12%
Sold by
- Andreas Halvorsen - Viking Global Investors cut 2.2% → 1.6%
- Stanley Druckenmiller - Duquesne Family Office cut 2.1% → 0.13%
-
10 SPY Spdr S&P 500 ETF Tr 10 bought · 5 sold +$113M
Bought by
- Hillman Capital Management added 0.44% → 1.4%
- George Soros - Soros Fund Management opened 1.0% of book
- Don Yacktman - Yacktman Asset Management added 0.04% → 0.26%
- Farallon Capital Management opened 0.24% of book
- Vulcan Value Partners opened 0.13% of book
- Samantha Mclemore - Patient Capital Management added 0.04% → 0.09%
- First Eagle Investment Management opened 0.06% of book
- Bill Nygren / Oakmark - Harris Associates L P added <0.01% → 0.04%
and 2 more
Sold by
- Jana Partners Management cut 14.3% → 12.4%
- Lewis Sanders - Sanders Capital cut 0.72% → 0.70%
- Chris James - Meritage Group closed was 0.12%
- Murray Stahl - Horizon Kinetics Asset Management cut 0.01% → 0.01%
- Warren Buffett - Berkshire Hathaway closed was <0.01%
Not counted as buying: 150 IPOs, spin-offs and new listings.
Most sold
-
1 AMZN Amazon Com Inc. 11 bought · 23 sold −$2.2B
Sold by
- Josh Tarasoff - Greenlea Lane Capital Management cut 21.2% → 23.8%
- Altarock Partners cut 19.8% → 23.4%
- Triple Frond Partners cut 14.4% → 15.1%
- Polen Capital Management cut 12.4% → 11.6%
- Grant Wonders - Voyager Global Management cut 11.1% → 10.5%
- Ram Parameswaran - Octahedron Capital Management cut 10.2% → 5.1%
- Dan Loeb - Third Point cut 9.3% → 10.2%
- David Tepper - Appaloosa cut 8.9% → 8.8%
and 15 more
Bought by
- Alex Sacerdote - Whale Rock Capital Management added 7.5% → 9.1%
- Nehal Chopra - Ratan Capital Management added 7.8% → 7.1%
- Lee Ainslie - Maverick Capital added 5.5% → 6.9%
- Lewis Sanders - Sanders Capital added 3.0% → 4.1%
- Corvex Management added 3.7% → 3.4%
- Valueact Capital - Valueact Holdings opened 2.7% of book
- Stanley Druckenmiller - Duquesne Family Office opened 1.9% of book
- Davidson Kempner Capital Management opened 1.9% of book
and 3 more
-
2 DIS Disney Walt Co. 1 bought · 12 sold −$689M
Sold by
- Valueact Capital - Valueact Holdings cut 18.2% → 16.7%
- Lindsell Train cut 11.8% → 12.4%
- Kahn Brothers Group cut 6.7% → 8.5%
- Harry Burn - Sound Shore Management cut 3.0% → 2.9%
- Farallon Capital Management cut 2.7% → 2.5%
- Sarah Ketterer - Causeway Capital Management cut 2.6% → 2.1%
- Robert Olstein - Olstein Capital Management cut 2.6% → 2.7%
- First Eagle Investment Management cut 0.80% → 0.86%
and 4 more
Bought by
- Steven Check - Check Capital Management added <0.01% → 1.5%
-
3 WFC Wells Fargo & Co. 3 bought · 12 sold −$2.2B
Sold by
- Christopher Davis - Davis Selected Advisers cut 4.5% → 3.5%
- First Pacific Advisors cut 4.1% → 3.8%
- Harry Burn - Sound Shore Management cut 3.3% → 3.6%
- Hillman Capital Management closed was 3.1%
- Richard Pzena - Pzena Investment Management cut 2.8% → 3.3%
- Dodge & Cox cut 2.8% → 2.9%
- Tweedy, Browne Co. cut 2.3% → 3.2%
- Bill Nygren / Oakmark - Harris Associates L P cut 1.6% → 1.3%
and 4 more
Bought by
- Lee Ainslie - Maverick Capital opened 2.7% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.30% of book
- Torray Investment Partners opened 0.03% of book
-
4 BKNG Booking Holdings, Inc. 0 bought · 9 sold −$1.1B
Sold by
- Grant Wonders - Voyager Global Management cut 8.2% → 6.0%
- David Rolfe - Wedgewood Partners cut 5.5% → 5.7%
- Henry Ellenbogen - Durable Capital Partners cut 3.8% → 3.8%
- John Armitage - Egerton Capital (UK) cut 2.7% → 0.70%
- Stephen Mandel - Lone Pine Capital closed was 2.4%
- Don Yacktman - Yacktman Asset Management cut 1.5% → 0.13%
- Davidson Kempner Capital Management cut 1.1% → 0.74%
- George Soros - Soros Fund Management cut 0.37% → 0.16%
and 1 more
Bought by
No manager bought.
-
5 META Meta Platforms Inc. 9 bought · 18 sold −$1.1B
Sold by
- Brad Gerstner - Altimeter Capital Management cut 19.2% → 19.4%
- Pat Dorsey - Dorsey Asset Management cut 14.4% → 12.6%
- Terry Smith - Fundsmith cut 11.0% → 11.4%
- Lewis Sanders - Sanders Capital cut 10.7% → 10.3%
- David Rolfe - Wedgewood Partners cut 8.7% → 9.2%
- Christopher Davis - Davis Selected Advisers cut 8.7% → 8.5%
- Mala Gaonkar - Surgocap Partners cut 8.7% → 8.2%
- Ram Parameswaran - Octahedron Capital Management cut 6.7% → 0.47%
and 10 more
Bought by
- Stephen Mandel - Lone Pine Capital added 8.1% → 8.9%
- Glen Kacher - Light Street Capital Management added 4.9% → 5.8%
- Alex Sacerdote - Whale Rock Capital Management added 6.0% → 5.7%
- Dan Loeb - Third Point added 4.2% → 5.2%
- Nehal Chopra - Ratan Capital Management added 4.8% → 4.1%
- Cathie Wood - Ark Investment Management added 2.1% → 2.3%
- Senator Investment Group added 2.4% → 1.6%
- Grant Wonders - Voyager Global Management opened 1.2% of book
and 1 more
-
6 AAPL Apple Inc. 7 bought · 15 sold −$15.7B
Sold by
- Duan Yongping - H&H International Investment closed was 74.3%
- Mala Gaonkar - Surgocap Partners closed was 8.3%
- Jensen Investment Management cut 7.1% → 7.5%
- David Rolfe - Wedgewood Partners cut 7.0% → 8.1%
- Lewis Sanders - Sanders Capital cut 6.2% → 6.4%
- Andreas Halvorsen - Viking Global Investors closed was 4.1%
- Polen Capital Management cut 4.1% → 4.2%
- Glen Kacher - Light Street Capital Management cut 3.6% → 2.4%
and 7 more
Bought by
- Alex Sacerdote - Whale Rock Capital Management opened 1.7% of book
- Davidson Kempner Capital Management opened 0.23% of book
- Francois Rochon - Giverny Capital added 0.09% → 0.16%
- Kahn Brothers Group added 0.10% → 0.15%
- Arnold Van Den Berg - Van Den Berg Management I opened 0.06% of book
- Ruane, Cunniff & Goldfarb opened <0.01% of book
- Cathie Wood - Ark Investment Management added <0.01% → <0.01%
-
7 CRM Salesforce Inc. 3 bought · 11 sold −$2.3B
Sold by
- Valueact Capital - Valueact Holdings cut 27.2% → 22.1%
- Starboard Value cut 8.4% → 3.4%
- Vulcan Value Partners cut 6.4% → 4.2%
- Stephen Mandel - Lone Pine Capital cut 4.8% → 3.9%
- Farallon Capital Management cut 2.7% → 2.1%
- Brad Gerstner - Altimeter Capital Management cut 1.9% → 1.6%
- Bill Nygren / Oakmark - Harris Associates L P cut 1.8% → 0.59%
- First Eagle Investment Management cut 1.5% → 1.8%
and 3 more
Bought by
- Alex Sacerdote - Whale Rock Capital Management added 0.87% → 3.3%
- George Soros - Soros Fund Management added 0.62% → 1.5%
- Andreas Halvorsen - Viking Global Investors added 0.54% → 1.3%
-
8 FIS Fidelity National Information Services, Inc. 0 bought · 8 sold −$786M
Sold by
- Jana Partners Management cut 6.9% → 2.0%
- Harry Burn - Sound Shore Management cut 3.1% → 2.5%
- Senator Investment Group cut 3.0% → 0.59%
- Seth Klarman - Baupost Group closed was 2.3%
- Dodge & Cox cut 1.9% → 1.6%
- Wallace Weitz - Weitz Investment Management cut 1.7% → 1.1%
- Robert Olstein - Olstein Capital Management cut 1.2% → 1.1%
- First Eagle Investment Management closed was <0.01%
Bought by
No manager bought.
-
9 BAC Bank Amer Corp. 2 bought · 9 sold −$6.5B
Sold by
- Warren Buffett - Berkshire Hathaway cut 11.9% → 11.2%
- Dan Sundheim - D1 Capital Partners closed was 3.4%
- Richard Pzena - Pzena Investment Management cut 2.5% → 2.5%
- Bill Nygren / Oakmark - Harris Associates L P cut 1.8% → 1.7%
- Dodge & Cox cut 1.2% → 0.79%
- Tweedy, Browne Co. cut 0.96% → 1.3%
- Murphy Pohlad - Murphy Pohlad Asset Management cut 0.65% → 0.68%
- Steven Check - Check Capital Management cut 0.12% → 0.12%
and 1 more
Bought by
- Andreas Halvorsen - Viking Global Investors added 2.9% → 3.5%
- David Katz - Matrix Asset Advisors added 0.03% → 0.31%
-
10 GOOGL / GOOG Alphabet 17 bought · 24 sold −$2.7B
Sold by
- Triple Frond Partners cut 18.1% → 19.9%
- Tweedy, Browne Co. cut 13.9% → 9.6%
- Ruane, Cunniff & Goldfarb cut 10.7% → 12.2%
- First Pacific Advisors cut 10.7% → 12.2%
- Thomas Russo - Gardner Russo & Quinn cut 10.3% → 12.2%
- David Rolfe - Wedgewood Partners cut 8.4% → 9.2%
- Polen Capital Management cut 6.1% → 6.3%
- Alex Sacerdote - Whale Rock Capital Management cut 5.6% → 3.2%
and 16 more
Bought by
- Andrew Steginsky - Steginsky Capital added 24.9% → 27.1%
- Eric Mandelblatt - Soroban Capital Partners added 15.4% → 17.4%
- Altarock Partners added 10.9% → 13.3%
- Pat Dorsey - Dorsey Asset Management added 8.1% → 12.5%
- Ram Parameswaran - Octahedron Capital Management added 2.7% → 9.9%
- Lewis Sanders - Sanders Capital added 7.1% → 9.3%
- George Soros - Soros Fund Management added 1.2% → 3.8%
- Brad Gerstner - Altimeter Capital Management added 1.6% → 3.0%
and 9 more
Not counted as selling: 160 mergers and delistings.
Opened and closed
New positions started from zero, and positions sold down to zero. IPOs, spin-offs and mergers are left out.
Opened by the most managers
-
COF Capital One Financial Corp. 6 managers avg 2.8% of book · Chris James - Meritage Group, Stephen Mandel - Lone Pine Capital and 4 more
Opened by
- Chris James - Meritage Group opened 5.4% of book
- Stephen Mandel - Lone Pine Capital opened 4.3% of book
- John Armitage - Egerton Capital (UK) opened 3.2% of book
- Dan Loeb - Third Point opened 2.2% of book
- Dan Sundheim - D1 Capital Partners opened 1.4% of book
- Glenn Greenberg - Brave Warrior Advisors opened <0.01% of book
-
MSFT Microsoft Corp. 6 managers avg 1.4% of book · Ram Parameswaran - Octahedron Capital Management, Gavin Baker - Atreides Management and 4 more
Opened by
- Ram Parameswaran - Octahedron Capital Management opened 3.0% of book
- Gavin Baker - Atreides Management opened 2.9% of book
- Glenview Capital Management opened 1.1% of book
- Robert Vinall - Rv Capital AG opened 1.0% of book
- George Soros - Soros Fund Management opened 0.34% of book
- Francois Rochon - Giverny Capital opened 0.04% of book
-
UNH Unitedhealth Group Inc. 5 managers avg 1.2% of book · Andreas Halvorsen - Viking Global Investors, Senator Investment Group and 3 more
Opened by
- Andreas Halvorsen - Viking Global Investors opened 3.1% of book
- Senator Investment Group opened 1.1% of book
- Vulcan Value Partners opened 0.96% of book
- George Soros - Soros Fund Management opened 0.59% of book
- Francois Rochon - Giverny Capital opened 0.04% of book
-
NU Nu Hldgs Ltd 5 managers avg 0.78% of book · Dan Sundheim - D1 Capital Partners, Gavin Baker - Atreides Management and 3 more
Opened by
- Dan Sundheim - D1 Capital Partners opened 2.6% of book
- Gavin Baker - Atreides Management opened 0.86% of book
- Ryan Packard - Hiddenite Capital Partners opened 0.29% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.13% of book
- Polen Capital Management opened 0.06% of book
-
BA Boeing Co. 4 managers avg 8.5% of book · King Street Capital Management, Nehal Chopra - Ratan Capital Management and 2 more
Opened by
- King Street Capital Management opened 29.2% of book
- Nehal Chopra - Ratan Capital Management opened 3.2% of book
- Andreas Halvorsen - Viking Global Investors opened 1.7% of book
- Steven Check - Check Capital Management opened <0.01% of book
-
TSLA Tesla Inc. 4 managers avg 3.0% of book · Nehal Chopra - Ratan Capital Management, Lee Ainslie - Maverick Capital and 2 more
Opened by
- Nehal Chopra - Ratan Capital Management opened 10.8% of book
- Lee Ainslie - Maverick Capital opened 0.64% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.41% of book
- Mairs & Power opened <0.01% of book
-
CSGP Costar Group Inc. 4 managers avg 2.8% of book · Dennis Hong - Shawspring Partners, Polen Capital Management and 2 more
Opened by
- Dennis Hong - Shawspring Partners opened 8.6% of book
- Polen Capital Management opened 1.3% of book
- Chase Coleman - Tiger Global Management opened 0.88% of book
- Eric Mandelblatt - Soroban Capital Partners opened 0.45% of book
-
ACHC Acadia Healthcare Company In 4 managers avg 2.4% of book · Eric Khrom - Khrom Capital Management, Sachem Head Capital Management and 2 more
Opened by
- Eric Khrom - Khrom Capital Management opened 5.6% of book
- Sachem Head Capital Management opened 2.9% of book
- Lee Ainslie - Maverick Capital opened 0.74% of book
- David Einhorn - DME Capital Management opened 0.26% of book
-
LLY Eli Lilly & Co. 4 managers avg 2.2% of book · Stephen Mandel - Lone Pine Capital, John Armitage - Egerton Capital (UK) and 2 more
Opened by
- Stephen Mandel - Lone Pine Capital opened 4.5% of book
- John Armitage - Egerton Capital (UK) opened 2.5% of book
- Stanley Druckenmiller - Duquesne Family Office opened 1.3% of book
- George Soros - Soros Fund Management opened 0.39% of book
-
FERG Ferguson Enterprises Inc. 4 managers avg 1.8% of book · Seth Klarman - Baupost Group, Gavin Baker - Atreides Management and 2 more
Opened by
- Seth Klarman - Baupost Group opened 5.7% of book
- Gavin Baker - Atreides Management opened 1.1% of book
- Francois Rochon - Giverny Capital opened 0.21% of book
- Polen Capital Management opened <0.01% of book
Closed out by the most managers
-
AAPL Apple Inc. 7 managers was avg 13.4% of book · Duan Yongping - H&H International Investment, Mala Gaonkar - Surgocap Partners and 5 more
Closed by
- Duan Yongping - H&H International Investment closed was 74.3%
- Mala Gaonkar - Surgocap Partners closed was 8.3%
- Andreas Halvorsen - Viking Global Investors closed was 4.1%
- Dan Loeb - Third Point closed was 2.9%
- Gavin Baker - Atreides Management closed was 2.5%
- Terry Smith - Fundsmith closed was 1.4%
- John Armitage - Egerton Capital (UK) closed was 0.47%
-
AVGO Broadcom Inc. 4 managers was avg 0.99% of book · Stanley Druckenmiller - Duquesne Family Office, Lee Ainslie - Maverick Capital and 2 more
Closed by
- Stanley Druckenmiller - Duquesne Family Office closed was 1.4%
- Lee Ainslie - Maverick Capital closed was 1.2%
- Brad Gerstner - Altimeter Capital Management closed was 1.0%
- Davidson Kempner Capital Management closed was 0.35%
-
LINE Lineage Inc. 4 managers was avg 0.33% of book · Lee Ainslie - Maverick Capital, Brad Gerstner - Altimeter Capital Management and 2 more
Closed by
- Lee Ainslie - Maverick Capital closed was 0.53%
- Brad Gerstner - Altimeter Capital Management closed was 0.46%
- George Soros - Soros Fund Management closed was 0.28%
- Ron Baron - Bamco Inc. (Baron Capital) closed was 0.05%
-
GEV Ge Vernova Inc. 3 managers was avg 6.2% of book · Mala Gaonkar - Surgocap Partners, Stephen Mandel - Lone Pine Capital and 1 more
Closed by
- Mala Gaonkar - Surgocap Partners closed was 15.0%
- Stephen Mandel - Lone Pine Capital closed was 2.2%
- John Armitage - Egerton Capital (UK) closed was 1.5%
-
OXY Occidental Pete Corp. 3 managers was avg 3.4% of book · Francis Chou - Chou Associates Management, Duan Yongping - H&H International Investment and 1 more
Closed by
- Francis Chou - Chou Associates Management closed was 6.5%
- Duan Yongping - H&H International Investment closed was 2.9%
- Ryan Packard - Hiddenite Capital Partners closed was 0.94%
-
PDD Pdd Holdings Inc. 3 managers was avg 3.4% of book · Ram Parameswaran - Octahedron Capital Management, Duan Yongping - H&H International Investment and 1 more
Closed by
- Ram Parameswaran - Octahedron Capital Management closed was 5.9%
- Duan Yongping - H&H International Investment closed was 3.2%
- Dan Sundheim - D1 Capital Partners closed was 1.00%
-
AMD Advanced Micro Devices Inc. 3 managers was avg 2.6% of book · Estuary Capital Management, Ben Hoskin - Value Aligned Research Advisors and 1 more
Closed by
- Estuary Capital Management closed was 7.8%
- Ben Hoskin - Value Aligned Research Advisors closed was 0.07%
- Ron Baron - Bamco Inc. (Baron Capital) closed was 0.05%
-
ADBE Adobe Inc. 3 managers was avg 2.6% of book · Spencer Waxman - Shannon River Fund Management, David Tepper - Appaloosa and 1 more
Closed by
- Spencer Waxman - Shannon River Fund Management closed was 5.6%
- David Tepper - Appaloosa closed was 1.5%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.61%
-
MSFT Microsoft Corp. 3 managers was avg 2.3% of book · Josh Tarasoff - Greenlea Lane Capital Management, Dan Sundheim - D1 Capital Partners and 1 more
Closed by
- Josh Tarasoff - Greenlea Lane Capital Management closed was 5.1%
- Dan Sundheim - D1 Capital Partners closed was 1.3%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.63%
-
UBER Uber Technologies Inc. 3 managers was avg 1.9% of book · Estuary Capital Management, John Armitage - Egerton Capital (UK) and 1 more
Closed by
- Estuary Capital Management closed was 3.2%
- John Armitage - Egerton Capital (UK) closed was 2.6%
- Senator Investment Group closed was 0.04%
Where the money went
Net bought by sector, with price moves taken out. Pick a sector to see its names.
- Health Care 12.1% weight · −0.2 pts +$7.9B 46 bought · 27 sold
- Consumer Staples 4.1% weight · +0.7 pts +$3.6B 24 bought · 12 sold
- Real Estate 2.8% weight · no change +$2.7B 13 bought · 18 sold
- Utilities 1.6% weight · +0.1 pts −$1.3B 15 bought · 12 sold
- Energy 4.0% weight · no change −$1.3B 19 bought · 15 sold
- Materials 3.0% weight · −0.3 pts −$1.4B 14 bought · 24 sold
- Industrials 9.8% weight · −0.1 pts −$2.2B 33 bought · 40 sold
- Communication Services 10.0% weight · +0.1 pts −$4.6B 27 bought · 47 sold
- Consumer Discretionary 15.6% weight · +0.2 pts −$7.7B 32 bought · 54 sold
- Financials 18.1% weight · +0.2 pts −$21.5B 26 bought · 62 sold
- Information Technology 18.9% weight · −0.9 pts −$23.2B 27 bought · 62 sold
Names without a sector (funds, foreign listings, private shares): −$2.4B.
Who moved the most
The biggest new positions, measured against each manager’s own book, and the managers that traded the most of theirs.
Biggest new bets
- King Street Capital Management opened BA · Boeing Co. 29.2% of book
- Estuary Capital Management opened TAP · Molson Coors Beverage Co. 11.4% of book
- Nehal Chopra - Ratan Capital Management opened TSLA · Tesla Inc. 10.8% of book
- Alex Roepers - Atlantic Investment Management opened OSK · Oshkosh Corp. (OSK) 10.6% of book
- Jana Partners Management opened MKL · Markel Group, Inc. 9.2% of book
- Ben Hoskin - Value Aligned Research Advisors opened GEV · Ge Vernova Inc. 9.0% of book
Most active managers
- King Street Capital Management 2 opened · 2 closed · +$130M net 112% of book traded
- Ram Parameswaran - Octahedron Capital Management 8 opened · 5 closed · +$7M net 111% of book traded
- Duan Yongping - H&H International Investment 0 opened · 8 closed · −$17.3B net 104% of book traded
- Alex Roepers - Atlantic Investment Management 4 opened · 1 closed · −$14M net 94% of book traded
- Ben Hoskin - Value Aligned Research Advisors 11 opened · 8 closed · −$17M net 90% of book traded
- Dan Sundheim - D1 Capital Partners 16 opened · 15 closed · +$437M net 89% of book traded
What they hold
Most owned counts managers, with the change since last quarter. Largest is the share of the combined book, each manager counting once. Highest conviction is the average position among holders, three or more.
Most owned
- 1 GOOGL / GOOG Alphabet 71 managers +2
- 2 MSFT Microsoft Corp. 63 managers +3
- 3 AMZN Amazon Com Inc. 51 managers +4
- 4 META Meta Platforms Inc. 42 managers +1
- 5 BRK.B / BRK.A Berkshire Hathaway 35 managers −1
- 6 V Visa Inc. 34 managers +1
- 7 TSM Taiwan Semiconductor Mfg Ltd 33 managers +3
- 8 AAPL Apple Inc. 31 managers −3
- 9 UNH Unitedhealth Group Inc. 31 managers +4
- 10 MA Mastercard Inc. 29 managers +1
Largest
- 1 GOOGL / GOOG Alphabet 3.4% held by 71
- 2 BRK.B / BRK.A Berkshire Hathaway 2.7% held by 35
- 3 MSFT Microsoft Corp. 2.4% held by 63
- 4 AMZN Amazon Com Inc. 1.9% held by 51
- 5 CVNA Carvana Co. 1.7% held by 9
- 6 META Meta Platforms Inc. 1.7% held by 42
- 7 V Visa Inc. 0.98% held by 34
- 8 MA Mastercard Inc. 0.76% held by 29
- 9 TSM Taiwan Semiconductor Mfg Ltd 0.73% held by 33
- 10 NVDA Nvidia Corporation 0.72% held by 25
Highest conviction
- 1 CVNA Carvana Co. avg 25.4% held by 9
- 2 LOAR Loar Holdings Inc. avg 14.9% held by 3
- 3 GPI Group 1 Automotive Inc. avg 10.5% held by 3
- 4 BRK.B / BRK.A Berkshire Hathaway avg 10.4% held by 35
- 5 I3N Chart Inds Inc. avg 10.1% held by 3
- 6 TDG Transdigm Group Inc. avg 10.1% held by 6
- 7 UTHR United Therapeutics Corp. avg 9.2% held by 3
- 8 SNX Td Synnex Corporation avg 8.8% held by 6
- 9 FICO Fair Isaac Corp. avg 8.6% held by 6
- 10 VFC Vf Corp. avg 8.5% held by 3
Did the combined book beat SPY?
Each quarter’s combined book held to the next quarter-end, at the 13Fs’ own prices. Price only, no dividends, and today’s managers throughout. Nobody could have copied it: 13Fs arrive about 45 days after the quarter ends.
Combined book, 8 quarters
+44.2%
SPY
+37.2%
Difference
+6.9 pts
2024 Q2, the start
+0.0% Combined book
+0.0% SPY
2024 Q3, since 2024 Q2
+7.5% Combined book
+5.4% SPY
That quarter: book +7.5%, SPY +5.4%
2024 Q4, since 2024 Q2
+10.2% Combined book
+7.7% SPY
That quarter: book +2.6%, SPY +2.1%
2025 Q1, since 2024 Q2
+6.0% Combined book
+2.8% SPY
That quarter: book −3.8%, SPY −4.6%
2025 Q2, since 2024 Q2
+18.3% Combined book
+13.5% SPY
That quarter: book +11.6%, SPY +10.5%
2025 Q3, since 2024 Q2
+29.0% Combined book
+22.4% SPY
That quarter: book +9.1%, SPY +7.8%
2025 Q4, since 2024 Q2
+31.8% Combined book
+25.3% SPY
That quarter: book +2.1%, SPY +2.4%
2026 Q1, since 2024 Q2
+25.9% Combined book
+19.5% SPY
That quarter: book −4.4%, SPY −4.6%
2026 Q2, since 2024 Q2
+44.2% Combined book
+37.2% SPY
That quarter: book +14.5%, SPY +14.8%
Quarter by quarter
| Quarter | Each manager once | By dollars | SPY | Book − SPY | Managers |
|---|---|---|---|---|---|
| 2026 Q2 | +14.5% | +11.5% | +14.8% | −0.4 pts | 133 |
| 2026 Q1 | −4.4% | −4.2% | −4.6% | +0.2 pts | 136 |
| 2025 Q4 | +2.1% | +2.6% | +2.4% | −0.2 pts | 136 |
| 2025 Q3 | +9.1% | +6.3% | +7.8% | +1.2 pts | 136 |
| 2025 Q2 | +11.6% | +8.0% | +10.5% | +1.1 pts | 136 |
| 2025 Q1 | −3.8% | −2.0% | −4.6% | +0.7 pts | 136 |
| 2024 Q4 | +2.6% | +1.1% | +2.1% | +0.4 pts | 134 |
| 2024 Q3 | +7.5% | +6.9% | +5.4% | +2.1 pts | 133 |
All 2,388 names
Download CSVShowing 300 of 350 matching names. The CSV has every name.
| Ticker | Company | Sector | Held by | Weight | Net bought | Bought / sold | Opened / closed |
|---|---|---|---|---|---|---|---|
| UNH | Unitedhealth Group Inc. | Health Care | 31 +4 | 0.49% | −$578M | 10 / 11 | 5 / 1 |
| TMO | Thermo Fisher Scientific Inc. | Health Care | 16 +1 | 0.21% | +$460M | 7 / 4 | 2 / 1 |
| DHR | Danaher Corporation | Health Care | 15 −1 | 0.21% | +$41M | 3 / 8 | 1 / 2 |
| LLY | Eli Lilly & Co. | Health Care | 15 +3 | 0.17% | +$1.7B | 8 / 3 | 4 / 1 |
| JNJ | Johnson & Johnson | Health Care | 14 −2 | 0.17% | −$88M | 2 / 5 | 0 / 2 |
| ABBV | Abbvie Inc. | Health Care | 13 +3 | 0.05% | +$72M | 4 / 1 | 3 / 0 |
| ELV | Elevance Health Inc. | Health Care | 12 | 0.32% | +$1.5B | 7 / 2 | 2 / 2 |
| CVS | Cvs Health Corp. | Health Care | 12 −2 | 0.28% | +$1B | 6 / 6 | 1 / 3 |
| BMY | Bristol-Myers Squibb Co. | Health Care | 12 | 0.16% | +$121M | 3 / 6 | 2 / 2 |
| MRK | Merck & Co. Inc. | Health Care | 12 −1 | 0.12% | +$290M | 3 / 5 | 2 / 3 |
| HCA | Hca Healthcare Inc. | Health Care | 11 | 0.21% | +$72M | 3 / 3 | 1 / 1 |
| PFE | Pfizer Inc. | Health Care | 11 | 0.15% | +$315M | 4 / 6 | 1 / 1 |
| GEHC | Ge Healthcare Technologies, Inc. | Health Care | 10 +1 | 0.16% | +$204M | 4 / 1 | 1 / 0 |
| CI | The Cigna Group | Health Care | 9 | 0.14% | −$91M | 1 / 3 | 0 / 0 |
| TEVA | Teva Pharmaceutical Inds Ltd | Health Care | 9 | 0.11% | +$118M | 2 / 4 | 0 / 0 |
| ILMN | Illumina Inc. | Health Care | 9 +1 | 0.10% | −$18M | 3 / 5 | 2 / 1 |
| ZBH | Zimmer Biomet Holdings, Inc. | Health Care | 9 +1 | 0.09% | +$294M | 2 / 2 | 1 / 0 |
| BAX | Baxter International, Inc. | Health Care | 9 +1 | 0.08% | +$245M | 3 / 4 | 1 / 0 |
| ABT | Abbott Labs | Health Care | 9 | 0.05% | −$144M | 0 / 1 | 0 / 0 |
| HUM | Humana, Inc. | Health Care | 8 | 0.10% | +$1.6B | 4 / 3 | 2 / 2 |
| MDT | Medtronic PLC | Health Care | 8 −2 | 0.09% | −$221M | 3 / 4 | 0 / 2 |
| ZTS | Zoetis Inc. | Health Care | 8 −1 | 0.08% | +$168M | 1 / 2 | 0 / 1 |
| BSX | Boston Scientific Corp. | Health Care | 8 | 0.07% | +$9M | 1 / 3 | 0 / 0 |
| EW | Edwards Lifesciences Corp. | Health Care | 8 +1 | 0.05% | −$4M | 2 / 4 | 2 / 1 |
| ICLR | Icon PLC | Health Care | 8 +4 | 0.05% | +$123M | 5 / 3 | 4 / 0 |
| BDX | Becton Dickinson & Co. | Health Care | 8 +1 | 0.05% | +$431M | 3 / 2 | 1 / 0 |
| AMGN | Amgen Inc. | Health Care | 8 | 0.04% | +$10M | 3 / 3 | 1 / 1 |
| NTRA | Natera Inc. | Health Care | 7 | 0.21% | −$38M | 1 / 2 | 0 / 0 |
| INSM | Insmed Inc. | Health Care | 7 +1 | 0.15% | −$502K | 3 / 2 | 1 / 0 |
| WST | Western Alliance Bancorp | Health Care | 7 −1 | 0.13% | −$167M | 3 / 4 | 0 / 1 |
| THC | Tenet Healthcare Corp. | Health Care | 7 −2 | 0.11% | −$124M | 1 / 7 | 0 / 2 |
| ISRG | Intuitive Surgical Inc. | Health Care | 7 +1 | 0.04% | −$114M | 1 / 3 | 1 / 0 |
| NVO | Novo-Nordisk A S | Health Care | 7 −1 | 0.03% | −$68M | 0 / 4 | 0 / 1 |
| BIIB | Biogen Inc. | Health Care | 6 +1 | 0.15% | +$63M | 3 / 1 | 1 / 0 |
| GSK | Gsk PLC | Health Care | 6 | 0.09% | +$13M | 2 / 2 | 0 / 0 |
| IQV | Iqvia Hldgs Inc. | Health Care | 6 +1 | 0.07% | +$267M | 4 / 0 | 1 / 0 |
| AVTR | Avantor, Inc. | Health Care | 6 | 0.06% | +$601M | 3 / 2 | 0 / 0 |
| DGX | Quest Diagnostics Inc. | Health Care | 6 | 0.03% | −$6M | 0 / 1 | 0 / 0 |
| ALGN | Align Technology Inc. | Health Care | 6 +1 | 0.01% | +$2M | 4 / 1 | 1 / 0 |
| MCK | Mckesson Corp. | Health Care | 5 +1 | 0.19% | +$226M | 1 / 2 | 1 / 0 |
| SOLV | Solventum Corporation | Health Care | 5 −2 | 0.14% | +$61M | 1 / 4 | 0 / 2 |
| OSCR | Oscar Health Inc. | Health Care | 5 −1 | 0.14% | −$14M | 2 / 2 | 0 / 1 |
| SYK | Stryker Corporation | Health Care | 5 | 0.10% | −$26M | 0 / 0 | 0 / 0 |
| ACHC | Acadia Healthcare Company In | Health Care | 5 +1 | 0.09% | −$103M | 4 / 4 | 4 / 3 |
| CRL | Charles Riv Labs Intl Inc. | Health Care | 5 | 0.07% | +$171M | 2 / 4 | 1 / 1 |
| CNC | Centene Corp. Del | Health Care | 5 | 0.07% | +$21M | 3 / 2 | 2 / 2 |
| SNY | Sanofi SA | Health Care | 5 −2 | 0.05% | −$66M | 1 / 4 | 0 / 2 |
| BNTX | Biontech Se | Health Care | 5 −1 | 0.05% | +$86M | 2 / 1 | 0 / 1 |
| TECH | Bio Techne Corp. | Health Care | 5 | 0.03% | −$304K | 1 / 2 | 0 / 0 |
| HSIC | Henry Schein, Inc. | Health Care | 5 +1 | 0.03% | +$137M | 3 / 0 | 1 / 0 |
| MEDP | Medpace Holdings Inc. | Health Care | 5 +1 | 0.03% | +$64M | 4 / 0 | 1 / 0 |
| NAMS | Newamsterdam Pharma Company | Health Care | 5 +1 | 0.02% | −$32M | 1 / 2 | 1 / 0 |
| REGN | Regeneron Pharmaceuticals, Inc. | Health Care | 5 −2 | 0.02% | −$28M | 1 / 4 | 1 / 3 |
| NVS | Novartis AG | Health Care | 5 | 0.01% | −$674K | 1 / 1 | 0 / 0 |
| VEEV | Veeva Sys Inc. | Health Care | 5 | 0.01% | −$200M | 2 / 3 | 1 / 1 |
| BHC | Bausch Health Companies Inc. | Health Care | 4 −1 | 0.13% | −$2M | 0 / 1 | 0 / 1 |
| CAH | Cardinal Health Inc. | Health Care | 4 −3 | 0.11% | −$302M | 0 / 3 | 0 / 3 |
| BMRN | Biomarin Pharmaceutical, Inc. | Health Care | 4 −1 | 0.11% | +$83M | 2 / 1 | 0 / 1 |
| VTRS | Viatris Inc. | Health Care | 4 −2 | 0.11% | +$2M | 1 / 3 | 0 / 2 |
| BIO | Bio Rad Labs Inc. | Health Care | 4 | 0.06% | +$57M | 1 / 0 | 0 / 0 |
| A | Agilent Technologies Inc. | Health Care | 4 −1 | 0.05% | −$148M | 0 / 1 | 0 / 1 |
| RPRX | Royalty Pharma PLC | Health Care | 4 | 0.05% | +$22M | 2 / 1 | 0 / 0 |
| IDXX | Idexx Labs Inc. | Health Care | 4 | 0.05% | +$34M | 1 / 0 | 0 / 0 |
| ALKS | Alkermes PLC | Health Care | 4 | 0.05% | −$3M | 0 / 1 | 0 / 0 |
| NBIX | Neurocrine Biosciences, Inc. | Health Care | 4 | 0.05% | +$210M | 2 / 1 | 0 / 0 |
| NVST | Envista Holdings Corporation | Health Care | 4 +1 | 0.04% | +$3M | 2 / 2 | 1 / 0 |
| SNDX | Syndax Pharmaceuticals Inc. | Health Care | 4 | 0.03% | −$12M | 0 / 1 | 0 / 0 |
| INCY | Incyte Corp. | Health Care | 4 | 0.03% | +$760K | 1 / 2 | 0 / 0 |
| MTD | Mettler Toledo International | Health Care | 4 +1 | 0.03% | −$10M | 1 / 0 | 1 / 0 |
| HOLX | Hologic, Inc. | Health Care | 4 | 0.03% | +$720K | 3 / 1 | 1 / 1 |
| GILD | Gilead Sciences, Inc. | Health Care | 4 | 0.03% | +$4M | 2 / 1 | 0 / 0 |
| BHVN | Biohaven Ltd | Health Care | 4 | 0.03% | +$21M | 2 / 1 | 0 / 0 |
| EWTX | Edgewise Therapeutics Inc. | Health Care | 4 +1 | 0.03% | −$7M | 1 / 3 | 1 / 0 |
| PCVX | Vaxcyte Inc. | Health Care | 4 −1 | 0.02% | +$18M | 2 / 3 | 0 / 1 |
| RCKT | Rocket Pharmaceuticals Inc. | Health Care | 4 | 0.02% | +$8M | 3 / 1 | 0 / 0 |
| VRTX | Vertex Pharmaceuticals | Health Care | 4 −1 | 0.02% | −$67M | 0 / 4 | 0 / 1 |
| URGN | Urogen Pharma Ltd | Health Care | 4 | 0.01% | −$1M | 2 / 1 | 0 / 0 |
| COO | Cooper Cos Inc. | Health Care | 4 +1 | 0.01% | +$188M | 2 / 0 | 1 / 0 |
| UTHR | United Therapeutics Corp. | Health Care | 3 | 0.21% | +$1M | 1 / 1 | 0 / 0 |
| EXEL | Exelixis Inc. | Health Care | 3 | 0.17% | −$66M | 1 / 1 | 0 / 0 |
| JAZZ | Jazz Pharmaceuticals PLC | Health Care | 3 | 0.14% | −$28M | 0 / 2 | 0 / 0 |
| RVMD | Revolution Medicines Inc. | Health Care | 3 | 0.09% | +$74M | 2 / 1 | 0 / 0 |
| WAT | Waters Corp. | Health Care | 3 | 0.08% | +$4M | 0 / 1 | 0 / 0 |
| SGRY | Surgery Partners Inc. | Health Care | 3 −1 | 0.08% | +$22M | 2 / 2 | 0 / 1 |
| IONS | Ionis Pharmaceuticals Inc. | Health Care | 3 | 0.06% | −$20M | 0 / 2 | 0 / 0 |
| SHC | Sotera Health Co. | Health Care | 3 | 0.05% | −$43M | 1 / 1 | 1 / 1 |
| UHS | Universal Hlth Svcs Inc. | Health Care | 3 −1 | 0.05% | +$32M | 1 / 1 | 0 / 1 |
| ALNY | Alnylam Pharmaceuticals, Inc. | Health Care | 3 | 0.04% | −$19M | 0 / 0 | 0 / 0 |
| ASND | Ascendis Pharma A/S | Health Care | 3 −1 | 0.04% | −$6M | 1 / 2 | 0 / 1 |
| ROIV | Roivant Sciences Ltd | Health Care | 3 | 0.04% | −$75M | 0 / 1 | 0 / 0 |
| XENE | Xenon Pharmaceuticals Inc. | Health Care | 3 | 0.03% | −$13M | 0 / 1 | 0 / 0 |
| LH | Labcorp Holdings Inc. | Health Care | 3 | 0.03% | −$5M | 0 / 1 | 0 / 0 |
| DXCM | Dexcom Inc. | Health Care | 3 | 0.03% | −$4M | 1 / 1 | 0 / 0 |
| INSP | Inspire Med Sys Inc. | Health Care | 3 +1 | 0.02% | +$164M | 2 / 0 | 1 / 0 |
| PBH | Prestige Consmr Healthcare I | Health Care | 3 | 0.02% | −$2M | 0 / 1 | 0 / 0 |
| GKOS | Glaukos Corp. | Health Care | 3 | 0.02% | −$26M | 0 / 1 | 0 / 0 |
| BEAM | Beam Therapeutics Inc. | Health Care | 3 | 0.02% | +$14M | 1 / 0 | 0 / 0 |
| CNTA | Centessa Pharmaceuticals PLC | Health Care | 3 | 0.02% | −$6M | 1 / 2 | 0 / 0 |
| DVA | Davita Inc. | Health Care | 3 | 0.02% | −$3M | 0 / 1 | 0 / 0 |
| DNA | Ginkgo Bioworks Holdings Inc. | Health Care | 3 | 0.02% | +$906K | 1 / 1 | 0 / 0 |
| KYMR | Kymera Therapeutics Inc. | Health Care | 3 +1 | 0.02% | +$5M | 1 / 0 | 1 / 0 |
| AXSM | Axsome Therapeutics Inc. | Health Care | 3 | 0.01% | −$9M | 1 / 1 | 0 / 0 |
| RARE | Ultragenyx Pharmaceutical In | Health Care | 3 −1 | 0.01% | −$17M | 0 / 3 | 0 / 1 |
| DYN | Dyne Therapeutics Inc. | Health Care | 3 | <0.01% | −$6M | 0 / 2 | 0 / 0 |
| LXEO | Lexeo Therapeutics Inc. | Health Care | 3 +1 | <0.01% | −$199K | 2 / 1 | 1 / 0 |
| BCYC | Bicycle Therapeutics Plc-Adr | Health Care | 3 −1 | <0.01% | −$23K | 1 / 1 | 0 / 1 |
| IMVT | Immunovant Inc. | Health Care | 3 −2 | <0.01% | −$24M | 1 / 3 | 0 / 2 |
| STOK | Stoke Therapeutics Inc. | Health Care | 3 +1 | <0.01% | −$125K | 1 / 1 | 1 / 0 |
| Masimo | Masimo Corp. | Health Care | 3 | <0.01% | −$149M | 0 / 2 | 0 / 0 |
| CDNA | Caredx Inc. | Health Care | 3 | <0.01% | −$6M | 1 / 2 | 0 / 0 |
| NUVB | Nuvation Bio Inc. | Health Care | 3 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| BKD | Brookdale Sr Living Inc. | Health Care | 3 +1 | <0.01% | −$2M | 2 / 1 | 1 / 0 |
| PGNY | Progyny Inc. | Health Care | 3 +1 | <0.01% | −$15M | 1 / 2 | 1 / 0 |
| MDGL | Madrigal Pharmaceuticals Inc. | Health Care | 2 | 0.28% | $0 | 0 / 0 | 0 / 0 |
| NVAX | Novavax Inc. | Health Care | 2 −1 | 0.13% | −$7M | 1 / 1 | 0 / 1 |
| FOLD | Amicus Therapeutics Inc. | Health Care | 2 | 0.08% | −$5M | 0 / 1 | 0 / 0 |
| INDV | Indivior PLC | Health Care | 2 | 0.07% | −$10M | 0 / 1 | 0 / 0 |
| ARVN | Arvinas Inc. | Health Care | 2 | 0.06% | +$5M | 1 / 1 | 0 / 0 |
| OGN | Organon & Company | Health Care | 2 | 0.06% | −$7M | 0 / 1 | 0 / 0 |
| ENTA | Enanta Pharmaceuticals Inc. | Health Care | 2 | 0.05% | $0 | 0 / 0 | 0 / 0 |
| IDYA | Ideaya Biosciences Inc. | Health Care | 2 | 0.05% | −$6M | 1 / 1 | 0 / 0 |
| WGS | Genedx Holdings Corp. | Health Care | 2 +1 | 0.04% | +$15M | 1 / 0 | 1 / 0 |
| CYTK | Cytokinetics Inc. | Health Care | 2 −2 | 0.04% | −$9M | 0 / 3 | 0 / 2 |
| AVAH | Aveanna Healthcare Hldgs Inc. | Health Care | 2 +1 | 0.03% | +$2M | 1 / 0 | 1 / 0 |
| FTRE | Fortrea Hldgs Inc. | Health Care | 2 −3 | 0.03% | −$51M | 1 / 4 | 0 / 3 |
| BLCO | Bausch Plus Lomb Corp. | Health Care | 2 −1 | 0.03% | +$3M | 1 / 1 | 0 / 1 |
| NVCR | Novocure Ltd | Health Care | 2 | 0.03% | +$7M | 1 / 0 | 0 / 0 |
| LQDA | Liquidia Corporation | Health Care | 2 | 0.03% | $0 | 0 / 0 | 0 / 0 |
| AXGN | Axogen Inc. | Health Care | 2 | 0.03% | −$1M | 0 / 1 | 0 / 0 |
| IOVA | Iovance Biotherapeutics Inc. | Health Care | 2 | 0.03% | $0 | 0 / 0 | 0 / 0 |
| MIRM | Mirum Pharmaceuticals Inc. | Health Care | 2 | 0.02% | −$3M | 0 / 1 | 0 / 0 |
| CRSP | Crispr Therapeutics AG | Health Care | 2 | 0.02% | +$58M | 1 / 0 | 0 / 0 |
| BBIO | Bridgebio Pharma Inc. | Health Care | 2 | 0.02% | +$67M | 1 / 0 | 0 / 0 |
| LNTH | Lantheus Hldgs Inc. | Health Care | 2 | 0.02% | +$211M | 2 / 0 | 0 / 0 |
| Perrigo | Perrigo Company PLC | Health Care | 2 | 0.02% | +$315K | 1 / 1 | 1 / 1 |
| TWST | Twist Bioscience Corp. | Health Care | 2 | 0.02% | −$4M | 0 / 1 | 0 / 0 |
| PRVA | Privia Health Group Inc. | Health Care | 2 −1 | 0.02% | −$3M | 0 / 2 | 0 / 1 |
| PTGX | Protagonist Therapeutics Inc. | Health Care | 2 | 0.01% | +$3M | 0 / 0 | 0 / 0 |
| WVE | Wave Life Sciences Ltd | Health Care | 2 +1 | 0.01% | −$21M | 1 / 1 | 1 / 0 |
| TRVI | Trevi Therapeutics Inc. | Health Care | 2 | 0.01% | −$1M | 0 / 1 | 0 / 0 |
| LKFT | Galapagos NV | Health Care | 2 | 0.01% | $0 | 0 / 0 | 0 / 0 |
| NRIX | Nurix Therapeutics Inc. | Health Care | 2 −1 | 0.01% | −$15M | 0 / 3 | 0 / 1 |
| VCYT | Veracyte Inc. | Health Care | 2 | 0.01% | −$38M | 0 / 2 | 0 / 0 |
| TALK | Talkspace Inc. | Health Care | 2 −1 | 0.01% | −$5M | 1 / 2 | 0 / 1 |
| DOCS | Doximity Inc. | Health Care | 2 +1 | 0.01% | −$225M | 1 / 1 | 1 / 0 |
| FMS | Fresenius Medical Care AG | Health Care | 2 | <0.01% | −$21M | 0 / 1 | 0 / 0 |
| CRNX | Crinetics Pharmaceuticals In | Health Care | 2 −1 | <0.01% | +$133M | 1 / 2 | 0 / 1 |
| ORIC | Oric Pharmaceuticals Inc. | Health Care | 2 | <0.01% | +$2M | 1 / 1 | 0 / 0 |
| VNDA | Vanda Pharmaceuticals Inc. | Health Care | 2 | <0.01% | −$6M | 0 / 1 | 0 / 0 |
| ADPT | Adaptive Biotechnologies Cor | Health Care | 2 | <0.01% | −$13M | 0 / 1 | 0 / 0 |
| CATX | Perspective Therapeutics Inc. | Health Care | 2 | <0.01% | −$3M | 0 / 2 | 0 / 0 |
| BFLY | Butterfly Network Inc. | Health Care | 2 | <0.01% | −$8M | 0 / 1 | 0 / 0 |
| PHG | Koninklijke Philips NV | Health Care | 2 | <0.01% | +$8M | 2 / 0 | 0 / 0 |
| NUVL | Nuvalent Inc. | Health Care | 2 | <0.01% | −$431K | 0 / 1 | 0 / 0 |
| VKTX | Viking Therapeutics Inc. | Health Care | 2 −1 | <0.01% | −$35M | 0 / 3 | 0 / 1 |
| SDGR | Schrodinger Inc. | Health Care | 2 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| ALLO | Allogene Therapeutics Inc. | Health Care | 2 | <0.01% | +$406K | 1 / 0 | 0 / 0 |
| XRAY | Dentsply Sirona Inc. | Health Care | 2 | <0.01% | +$7M | 0 / 0 | 0 / 0 |
| BTI | British Amern Tob PLC | Health Care | 2 | <0.01% | −$507K | 1 / 1 | 0 / 0 |
| ITGR | Integer Hldgs Corp. | Health Care | 2 | <0.01% | +$11M | 1 / 0 | 0 / 0 |
| EMBC | Embecta Corp. | Health Care | 2 | <0.01% | −$3M | 0 / 1 | 0 / 0 |
| ELAN | Elanco Animal Health, Inc. | Health Care | 2 −1 | <0.01% | −$4M | 0 / 1 | 0 / 1 |
| LFST | Lifestance Health Group Inc. | Health Care | 2 | <0.01% | −$3M | 1 / 1 | 0 / 0 |
| BWAY | Brainsway Ltd | Health Care | 2 +1 | <0.01% | +$1M | 1 / 1 | 1 / 0 |
| ALVO | Alvotech SA | Health Care | 2 | <0.01% | −$8M | 0 / 1 | 0 / 0 |
| TVTX | Travere Therapeutics Inc. | Health Care | 2 +1 | <0.01% | +$51M | 1 / 0 | 1 / 0 |
| TSHA | Taysha Gene Therapies Inc. | Health Care | 2 +1 | <0.01% | +$904K | 1 / 0 | 1 / 0 |
| BRKR | Bruker Corp. | Health Care | 2 +1 | <0.01% | +$3M | 1 / 1 | 1 / 0 |
| WAY | Waystar Hldg Corp. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$58M | 2 / 0 | 2 / 0 |
| NEOG | Neogen Corp. | Health Care | 2 | <0.01% | +$14M | 1 / 0 | 0 / 0 |
| SRTA | Blade Air Mobility Inc. | Health Care | 2 +1 | <0.01% | +$6M | 2 / 0 | 1 / 0 |
| CMPS | Compass Pathways PLC | Health Care | 2 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| EHC | Encompass Health Corp. | Health Care | 2 | <0.01% | +$41M | 1 / 1 | 0 / 0 |
| COGT | Cogent Biosciences Inc. | Health Care | 2 | <0.01% | −$6M | 0 / 1 | 0 / 0 |
| HQY | Healthequity Inc. | Health Care | 2 | <0.01% | +$3M | 0 / 0 | 0 / 0 |
| Compugen | Compugen Ltd | Health Care | 2 −1 | <0.01% | −$2M | 0 / 1 | 0 / 1 |
| PRME | Prime Medicine Inc. | Health Care | 2 −1 | <0.01% | −$4M | 0 / 2 | 0 / 1 |
| OSUR | Orasure Technologies Inc. | Health Care | 2 +1 | <0.01% | +$36K | 1 / 0 | 1 / 0 |
| ENOV | Enovis Corporation | Health Care | 2 | <0.01% | +$3M | 2 / 0 | 0 / 0 |
| IVVD | Invivyd Inc. | Health Care | 2 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| PEPG | Pepgen Inc. | Health Care | 2 | <0.01% | −$262K | 0 / 1 | 0 / 0 |
| RGEN | Repligen Corp. | Health Care | 2 | <0.01% | −$233K | 1 / 0 | 0 / 0 |
| DCGO | Docgo Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$2M | 2 / 0 | 2 / 0 |
| GRFS | Grifols S A | Health Care | 2 −1 | <0.01% | −$4M | 0 / 1 | 0 / 1 |
| RDNT | Radnet Inc. | Health Care | 2 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| CBLL | Ceribell Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$905K | 2 / 0 | 2 / 0 |
| COR | Cencora Inc. | Health Care | 2 +1 | <0.01% | −$52M | 1 / 1 | 1 / 0 |
| HROW | Harrow Health Inc. | Health Care | 1 | 0.17% | $0 | 0 / 0 | 0 / 0 |
| TGTX | Tg Therapeutics Inc. | Health Care | 1 | 0.09% | −$602K | 0 / 0 | 0 / 0 |
| STXS | Stereotaxis Inc. | Health Care | 1 | 0.06% | $0 | 0 / 0 | 0 / 0 |
| ACAD | Acadia Pharmaceuticals Inc. | Health Care | 1 | 0.06% | +$4M | 1 / 0 | 0 / 0 |
| ALC | Alcon AG | Health Care | 1 −1 | 0.05% | −$30M | 0 / 2 | 0 / 1 |
| ETON | Eton Pharmaceuticals Inc. | Health Care | 1 | 0.05% | +$960K | 0 / 0 | 0 / 0 |
| OCUL | Ocular Therapeutix Inc. | Health Care | 1 | 0.05% | −$6M | 0 / 1 | 0 / 0 |
| DNTH | Dianthus Therapeutics Inc. | Health Care | 1 | 0.05% | −$964K | 0 / 0 | 0 / 0 |
| ATRC | Atricure Inc. | Health Care | 1 | 0.04% | $0 | 0 / 0 | 0 / 0 |
| RYTM | Rhythm Pharmaceuticals Inc. | Health Care | 1 | 0.04% | $0 | 0 / 0 | 0 / 0 |
| LFCR | Lifecore Biomedical Inc. | Health Care | 1 | 0.03% | +$10M | 1 / 0 | 0 / 0 |
| PRTA | Prothena Corp. PLC | Health Care | 1 | 0.03% | $0 | 0 / 0 | 0 / 0 |
| CGON | Cg Oncology Inc. | Health Care | 1 | 0.02% | −$16M | 0 / 1 | 0 / 0 |
| Bausch Lomb | Bausch Lomb Corp. IPO or spin-off | Health Care | 1 +1 | 0.02% | +$15M | 1 / 0 | 1 / 0 |
| TNDM | Tandem Diabetes Care Inc. | Health Care | 1 | 0.02% | +$684K | 1 / 0 | 0 / 0 |
| RXRX | Recursion Pharmaceuticals Inc. | Health Care | 1 | 0.01% | −$3M | 0 / 0 | 0 / 0 |
| Kalvista Pharmaceutic… | Kalvista Pharmaceuticals Inc. | Health Care | 1 | 0.01% | +$745K | 1 / 0 | 0 / 0 |
| ANAB | Anaptysbio Inc. | Health Care | 1 −1 | 0.01% | −$2M | 0 / 1 | 0 / 1 |
| TFX | Teleflex Incorporated | Health Care | 1 | 0.01% | +$29M | 1 / 0 | 0 / 0 |
| MYGN | Myriad Genetics Inc. | Health Care | 1 | 0.01% | +$40M | 1 / 0 | 0 / 0 |
| SUPN | Supernus Pharmaceuticals, Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| BCRX | Biocryst Pharmaceuticals Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| TMDX | Transmedics Group Inc. | Health Care | 1 −1 | <0.01% | +$8M | 1 / 1 | 0 / 1 |
| XOMA | Xoma Corp. Del | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| MOH | Molina Healthcare Inc. | Health Care | 1 | <0.01% | −$166M | 0 / 1 | 0 / 0 |
| COLL | Collegium Pharmaceutical Inc. | Health Care | 1 | <0.01% | +$594K | 1 / 0 | 0 / 0 |
| PHAT | Phathom Pharmaceuticals Inc. | Health Care | 1 | <0.01% | −$3M | 0 / 1 | 0 / 0 |
| TELA | Tela Bio Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$4M | 1 / 0 | 1 / 0 |
| PRQR | Proqr Therapeutics N V | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| HIMS | Hims & Hers Health Inc. | Health Care | 1 −1 | <0.01% | +$186M | 1 / 1 | 0 / 1 |
| KURA | Kura Oncology Inc. | Health Care | 1 | <0.01% | +$348K | 1 / 0 | 0 / 0 |
| RCUS | Arcus Biosciences Inc. | Health Care | 1 | <0.01% | −$37K | 0 / 0 | 0 / 0 |
| AGIO | Agios Pharmaceuticals Inc. | Health Care | 1 | <0.01% | +$447K | 0 / 0 | 0 / 0 |
| ZNTL | Zentalis Pharmaceuticals Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| PGEN | Precigen Inc. | Health Care | 1 | <0.01% | −$63K | 0 / 0 | 0 / 0 |
| LZAGY | Lonza Group Adr | Health Care | 1 | <0.01% | +$54K | 0 / 0 | 0 / 0 |
| PODD | Insulet Corp. | Health Care | 1 | <0.01% | −$914K | 0 / 1 | 0 / 0 |
| Enhabit | Enhabit Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| CNTX | Context Therapeutics Inc. | Health Care | 1 | <0.01% | +$63K | 0 / 0 | 0 / 0 |
| ORKA | Oruka Therapeutics Inc. | Health Care | 1 | <0.01% | −$9M | 0 / 1 | 0 / 0 |
| ARAY | Accuray Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| IART | Integra Lifesciences Hldgs | Health Care | 1 −1 | <0.01% | −$56M | 0 / 2 | 0 / 1 |
| ABCL | Abcellera Biologics Inc. | Health Care | 1 | <0.01% | +$483K | 1 / 0 | 0 / 0 |
| INGN | Inogen Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| COYA | Coya Therapeutics Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| BCAX | Bicara Therapeutics Inc. | Health Care | 1 −1 | <0.01% | +$1M | 1 / 2 | 1 / 2 |
| MLYS | Mineralys Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ALEC | Alector Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| IPSC | Century Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ALHC | Alignment Healthcare Inc. | Health Care | 1 | <0.01% | −$10M | 0 / 1 | 0 / 0 |
| RZLT | Rezolute Inc. | Health Care | 1 | <0.01% | −$8K | 0 / 0 | 0 / 0 |
| QURE | Uniqure NV | Health Care | 1 | <0.01% | −$8M | 0 / 1 | 0 / 0 |
| ARGX | Argenx Se | Health Care | 1 −1 | <0.01% | −$28M | 0 / 1 | 0 / 1 |
| HALO | Halozyme Therapeutics | Health Care | 1 | <0.01% | +$17K | 0 / 0 | 0 / 0 |
| GH | Guardant Health Inc. | Health Care | 1 | <0.01% | −$2M | 0 / 0 | 0 / 0 |
| LRMR | Larimar Therapeutics Inc. | Health Care | 1 | <0.01% | −$475K | 0 / 1 | 0 / 0 |
| AUTL | Autolus Therapeutics PLC | Health Care | 1 | <0.01% | +$235K | 1 / 0 | 0 / 0 |
| DMAC | Diamedica Therapeutics Inc. | Health Care | 1 | <0.01% | +$615K | 1 / 0 | 0 / 0 |
| PSNL | Personalis Inc. | Health Care | 1 | <0.01% | −$2M | 0 / 0 | 0 / 0 |
| NGNE | Neurogene Inc. | Health Care | 1 −1 | <0.01% | −$9M | 1 / 1 | 0 / 1 |
| ARCT | Arcturus Therapeutics Holdings | Health Care | 1 | <0.01% | −$3M | 0 / 1 | 0 / 0 |
| SNN | Smith & Nephew PLC | Health Care | 1 | <0.01% | +$10M | 1 / 1 | 1 / 1 |
| CERS | Cerus Corp. | Health Care | 1 | <0.01% | +$4M | 1 / 0 | 0 / 0 |
| PYXS | Pyxis Oncology Inc. | Health Care | 1 | <0.01% | +$1M | 1 / 0 | 0 / 0 |
| GPCR | Structure Therapeutics Inc. | Health Care | 1 −1 | <0.01% | −$12M | 0 / 1 | 0 / 1 |
| SPRY | Ars Pharmaceuticals Inc. | Health Care | 1 −1 | <0.01% | −$6M | 0 / 2 | 0 / 1 |
| PHVS | Pharvaris N V | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| FHTX | Foghorn Therapeutics Inc. | Health Care | 1 | <0.01% | +$704K | 1 / 0 | 0 / 0 |
| ACRS | Aclaris Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| PVLA | Palvella Therapeutics Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$857K | 1 / 0 | 1 / 0 |
| RDY | Dr Reddy's Laboratories Ltd | Health Care | 1 | <0.01% | +$7M | 1 / 0 | 0 / 0 |
| VIR | Vir Biotechnology Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$734K | 1 / 0 | 1 / 0 |
| EOLS | Evolus Inc. | Health Care | 1 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| ABSI | Absci Corp. | Health Care | 1 | <0.01% | +$5M | 1 / 0 | 0 / 0 |
| ALDX | Aldeyra Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ACRV | Acrivon Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| TECX | Tectonic Therapeutic Inc. | Health Care | 1 | <0.01% | +$9M | 1 / 0 | 0 / 0 |
| IBIO | Ibio Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| CAPR | Capricor Therapeutics Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$31M | 1 / 0 | 1 / 0 |
| GUTS | Fractyl Health Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| TAK | Takeda Pharmaceutical Co. Ltd | Health Care | 1 | <0.01% | −$10M | 0 / 1 | 0 / 0 |
| CRMD | Cormedix Inc. | Health Care | 1 | <0.01% | +$11M | 1 / 0 | 0 / 0 |
| USNA | Usana Health Sciences Inc. | Health Care | 1 | <0.01% | +$1M | 0 / 0 | 0 / 0 |
| ZLAB | Zai Lab Ltd | Health Care | 1 −1 | <0.01% | −$51M | 0 / 1 | 0 / 1 |
| AQST | Aquestive Therapeutics Inc. | Health Care | 1 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| APRE | Aprea Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ADCT | Adc Therapeutics SA | Health Care | 1 | <0.01% | +$40K | 1 / 0 | 0 / 0 |
| ABEO | Abeona Therapeutics Inc. | Health Care | 1 | <0.01% | +$535K | 1 / 0 | 0 / 0 |
| ESTA | Establishment Labs Hldgs Inc. | Health Care | 1 −1 | <0.01% | +$4M | 1 / 1 | 0 / 1 |
| INBX | Inhibrx Biosciences Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| SYRE | Spyre Therapeutics Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| BDTX | Black Diamond Therapeutics I | Health Care | 1 | <0.01% | +$32K | 1 / 0 | 0 / 0 |
| VYGR | Voyager Therapeutics Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| TYRA | Tyra Biosciences Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$14M | 1 / 0 | 1 / 0 |
| GANX | Gain Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| TNGX | Tango Therapeutics Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$12M | 1 / 0 | 1 / 0 |
| RFL | Rafael Holding | Health Care | 1 | <0.01% | −$165K | 0 / 1 | 0 / 0 |
| ARWR | Arrowhead Pharmaceuticals In IPO or spin-off | Health Care | 1 +1 | <0.01% | +$12M | 1 / 0 | 1 / 0 |
| CMPX | Compass Therapeutics Inc. | Health Care | 1 | <0.01% | +$60K | 1 / 0 | 0 / 0 |
| RLMD | Relmada Therapeutics Inc. | Health Care | 1 −2 | <0.01% | −$389K | 0 / 3 | 0 / 2 |
| HSTM | Healthstream Inc. | Health Care | 1 | <0.01% | −$203K | 0 / 0 | 0 / 0 |
| AORT | Artivion Inc. | Health Care | 1 | <0.01% | −$862K | 0 / 0 | 0 / 0 |
| MRVI | Maravai Lifesciences Hldgs I | Health Care | 1 | <0.01% | +$436K | 0 / 0 | 0 / 0 |
| XERS | Xeris Biopharma Holdings Inc. | Health Care | 1 | <0.01% | −$106K | 0 / 1 | 0 / 0 |
| MRNA | Moderna Inc. | Health Care | 1 −1 | <0.01% | −$45M | 1 / 2 | 1 / 2 |
| PNTG | Pennant Group Inc. | Health Care | 1 | <0.01% | +$957K | 1 / 0 | 0 / 0 |
| ADGM | Adagio Med Hldgs Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| CRBU | Caribou Biosciences Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| AHCO | Adapthealth Corp. | Health Care | 1 | <0.01% | −$698K | 0 / 1 | 0 / 0 |
| Nanox Imaging | Nanox Imaging Ltd | Health Care | 1 | <0.01% | +$346K | 1 / 0 | 0 / 0 |
| CVRX | Cvrx Inc. | Health Care | 1 | <0.01% | −$1K | 0 / 0 | 0 / 0 |
| INFU | Infusystem Hldgs Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| Select Med | Select Med Hldgs Corp. | Health Care | 1 | <0.01% | +$1M | 1 / 0 | 0 / 0 |
How the numbers work
Same managers in both quarters
Changes compare only managers with a 13F in both 2024 Q3 and 2024 Q4: 134 this time. New in 2024 Q4: Situational Awareness, Kentucky Trust Co. - Kentucky Trust.
Buying versus price
Each holding’s dollar change splits into price (what last quarter’s shares earned by this quarter’s 13F price) and net bought (shares added or cut, times this quarter’s price), using each 13F’s own values. The two add back to the change exactly. Stock splits are adjusted first.
Who counts as a buyer or a seller
A manager bought a stock if it opened a position, or added at least 5% to its shares or a trade worth 0.25% of its book; it sold if it closed the position or cut it by the same amounts. Smaller changes count as holding, and a stock split never counts. A manager was a net buyer for the quarter when its trading added up to at least 0.25% of its book. GOOG and GOOGL count once.
IPOs, spin-offs and mergers
A stock no tracked manager held last quarter (an IPO, a spin-off, a new share class) is not counted as buying, and one nobody holds now (a merger, a delisting) is not counted as selling. Choose them under All names to see them.
Each manager once, or by dollars
By default every manager counts the same, so a list leads with what the most managers did. By dollars ranks by money moved and weighs holdings by size, so the largest books set the order.
Sectors
GICS sectors where the company has one. Funds, foreign listings and private shares have none; their buying is shown on its own, never filed under Other. Sector weights are shares of the names that have a sector.
The combined book against SPY
Each quarter-end’s combined book is held to the next quarter-end at the 13Fs’ own prices: price only, no dividends, and today’s featured managers for every quarter. SPY is the same filings’ price for SPY. It is a record of what the managers held, not something anyone could have copied, because 13Fs arrive about 45 days after the quarter ends.
What a 13F leaves out
Long US-listed stock only: no shorts, cash, bonds or foreign listings, and options are left out here.